Theratechnologies Inc (fka THER) (THER)

[Camaro1093]

Theratechnologies to Present at BioFinance 2010 Conference

MONTREAL, CANADA -- (MARKETWIRE) -- 04/05/10 --

Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and
Chief Executive Officer, will present an overview of the Company at the
BioFinance 2010 Conference, being held this week in Toronto. Mr. Rosconi will
be speaking at 11:00 a.m., on Wednesday, April 7, in the Trinity II Room of the
Toronto Marriott Eaton Centre.

BioFinance is the Canadian life science industry's leading investor
conference that brings together key industry players to consider investment
opportunities and issues affecting companies in biotechnology.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that
discovers and develops innovative therapeutic products, with an emphasis on
peptides, for commercialization. The Company targets unmet medical needs in
financially attractive specialty markets where it can retain all or part of the
commercial rights to its products. Its most advanced compound, tesamorelin, is
an analogue of the human growth hormone releasing factor. In 2009,
Theratechnologies submitted a New Drug Application to the U.S. Food and Drug
Administration, seeking approval of tesamorelin for the treatment of excess
abdominal fat in HIV-infected patients with lipodystrophy. The Company's growth
strategy is centered on the commercialization of tesamorelin in the United
States and in other markets for HIV-associated lipodystrophy, as well as the
development of clinical programs for tesamorelin in other medical conditions.

Contacts: Theratechnologies Inc. Andrea Gilpin Vice President, IR &
Communications 514-336-7800, ext. 205 [e-mail]

Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=zKXWTTW28PrVwqlfsS6Erg%3D%3D. You can use
this link on the day this article is published and the following day.


(END) Dow Jones Newswires

04-05-10 1037ET